Navigation Links
Laresse Dermal Filler Research Presented at Anti-Aging World,Congress

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed, Inc. announced today that a review of the company's research on novel, synthetic dermal fillers is being presented at the Anti-Aging Medical World Congress (AAMWC) in Monte Carlo March 22-24, 2007.

In 2006, FzioMed launched Laresse Dermal Filler, the first ultra-smooth, non-permanent, synthetic filler created from the company's patented polymer science. Laresse represents a completely new class of filler for the correction of wrinkles and lines caused by sun exposure, aging and other factors.

After extensive characterization of cross-linked hyaluronic acid (HA) fillers, FzioMed designed Laresse from biocompatible polymers to have key gel properties that offer significant advantages over common fillers being used today. For example, Laresse is stable without chemical cross-linking, completely free of both bacterial and animal by-products, and smoother and easier to inject than HA fillers.

Richard Berg, Ph.D., FzioMed's Chief Scientific Officer, will present "Novel Synthetic Dermal Fillers" at AAMWC on March 24th. His talk will describe the rheological properties of commercialized cross-linked HA fillers and includes data demonstrating the broader versatility and advantages of FzioMed's polymer technology for formulating a family of improved dermal fillers, including Laresse.

"This presentation highlights FzioMed's approach of applying science to the rapidly evolving field of soft tissue augmentation," said John Krelle, FzioMed President & Chief Executive Officer.

About Laresse

Laresse Dermal Filler is an ultra-smooth, non-permanent, non-HA gel composed of pure, absorbable medical polymers. Laresse is the first non-permanent filler without many of the drawbacks of HA and collagen fillers. No other filler offers the same features as Laresse: non-permanent wrinkle correction, non-animal and non-bacterial compone nts, easy injection through a very fine needle, and ultra-smooth texture and feel. Laresse is currently available only in the EU.

About FzioMed

FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company's patented science. FzioMed's polymer technology has uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the U.S., Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse dermal filler. FzioMed products are for investigational use only in the U.S.

FzioMed(R), Oxiplex(R) and Laresse(R) are trademarks of FzioMed, Inc.

Contact

FzioMed UK
Amanda Cameron, +44-800-902-0720
or
FzioMed USA
Jan W. Haynes, +805-546-0610


'"/>




Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. NIEHS Researchers Identify Enzyme Critical in DNA Replication
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
8. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
9. President Bush Ignores Americas Plea for Support of Stem Cell Research
10. Researchers Discover Gene For Rare Skin Disorder
11. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Research and Markets has announced the addition ... - Forecast to 2025" report to their offering. ... Global Optogenetics Market is ... next decade to reach approximately $76.24 million by 2025. ... growing count of labs using optogentic techniques for neurosciences, quick growth ...
(Date:1/24/2017)... -- For today, Stock-Callers.com scans the following Biotechnology ... Biopharmaceuticals Inc. (NASDAQ: ALDR ), BioDelivery Sciences International ... EGLT ). These equities are part of the ... rd , 2017, with the NYSE Health Care Index dropping ... S&P 500 also were down 0.3% as a group. These ...
(Date:1/24/2017)... INTRODUCTION Injectable drug delivery systems have ... vials to prefilled syringes, auto-injectors, pen injectors and ... preferred devices for parenteral administration of drugs. Specifically, ... strongly over the past several years. A growing ... format for delivering drugs. The popularity of prefilled ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... ... January 24, 2017 , ... In comments ... Research Institute (PCORI) for developing a data access and sharing policy. The nation’s ... data sharing plan as part of award applications, and earmarking specified amounts of ...
(Date:1/24/2017)... ... January 24, 2017 , ... The ... the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was ... coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few choices with ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food and Beverage Safety ... (PACE), at the International Production and Processing Expo (IPPE) in Atlanta, Georgia from ... technology that is used in poultry processing facilities to provide constant, real-time data ...
(Date:1/24/2017)... ... January 24, 2017 , ... Manzo Pharmaceuticals, LLC., announced that ... Trademark by the United States Patent and Trademark Office. The purpose of ... consumers into thinking that other products are similar to the patented Lacto-Freedom Probiotic. ...
Breaking Medicine News(10 mins):